Go back

Neglected disease funding rising but misdirected, says report

Investment in neglected disease R&D has grown in the past five years but is directed away from the development of drugs and vaccines, according to a report by Policy Cures, a research organisation specialising in neglected diseases.

The ‘Neglected disease R&D: Five-year review’ published on 3 December, found that spending on R&D rose by US$444 million between 2007 and 2011.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.